Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) | Finanzwire

Basculer en Français

9473	Companies
185423	Keywords
117773	Articles
99292	Press releases

Headlines Articles Press releases Aspire Biopharma Holdings, Inc.

Home
Companies
Aspire Biopharma Holdings, Inc.

BRIEF

published on 12/04/2025 at 15:05, 19 hours 14 minutes ago

Aspire Biopharma Reports Q3 2025 Business Developments

FDA Submission Sublingual Technology Aspire Biopharma BUZZ BOMB™ Q3 2025 Update
PRESS RELEASE

published on 12/04/2025 at 15:00, 19 hours 19 minutes ago

Aspire Biopharma Provides Q3 2025 Business Update
Aspire Biopharma updates Q3 2025 progress, including FDA submission, patent application, and BUZZ BOMB™ launch. Anticipates NDA for sublingual aspirin in H1 2026

Patent Application FDA Submission Aspire Biopharma BUZZ BOMB™ Launch NDA 2026
BRIEF

published on 12/02/2025 at 15:05, 2 days 19 hours ago

Aspire Biopharma Advances FDA Discussions for Sublingual Aspirin

FDA Submission Clinical Trial Results Aspire Biopharma Sublingual Aspirin Heart Attack Treatment
PRESS RELEASE

published on 12/02/2025 at 15:00, 2 days 19 hours ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire Biopharma Holdings, Inc. submits Pre-IND meeting request to FDA for fast-acting sublingual aspirin formulation to treat acute myocardial infarction, demonstrating rapid action and potential for FDA approval

Clinical Trial FDA Submission Aspire Biopharma Sublingual Aspirin Acute Myocardial Infarction
BRIEF

published on 11/26/2025 at 15:05, 8 days 19 hours ago

Aspire Biopharma Strengthens Team with New Appointment

Sublingual Delivery Aspire Biopharma Dr. Mark J. Jaroszeski DNA/drug Innovation Scientific Team
PRESS RELEASE

published on 11/26/2025 at 15:00, 8 days 19 hours ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Aspire Biopharma appoints Dr. Mark J. Jaroszeski, PhD as a key addition to its scientific team, enhancing drug delivery technology development and innovation

Drug Delivery Technology Sublingual Delivery Aspire Biopharma Mark J. Jaroszeski Medical Engineering
BRIEF

published on 11/06/2025 at 15:05, 28 days 19 hours ago

Aspire Biopharma Initiates Partnership Discussions at CPHI Frankfurt

Pharmaceutical Partnerships Drug Delivery Technology Aspire Biopharma Sublingual Aspirin CPHI Frankfurt
PRESS RELEASE

published on 11/06/2025 at 15:00, 28 days 19 hours ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Aspire Biopharma successfully participated in CPHI Frankfurt, engaging in strategic discussions with global pharma companies for its innovative sublingual high-dose aspirin. The event hosted 63,000+ attendees from 160 countries

Drug Delivery Technology Aspire Biopharma CPHI Frankfurt Sublingual High-dose Aspirin Pharmaceutical Event
BRIEF

published on 09/03/2025 at 14:35, 3 months 1 day ago

Aspire Biopharma Achieves Key Milestone with Sublingual Aspirin Trial for Heart Attack Treatment

FDA Approval Clinical Trial Sublingual Aspirin Heart Attack Treatment Thromboxane B2 Inhibition
PRESS RELEASE

published on 09/03/2025 at 14:30, 3 months 1 day ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire's sublingual aspirin formulation rapidly inhibits blood clotting by blocking platelet aggregation, showing potential for accelerated approval in Q3 2025

Clinical Trial Sublingual Aspirin Aspire TxB2 Inhibition Heart Attack

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 44 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 49 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 19 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 14 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 19 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:40, 39 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 49 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 14 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 18 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 1 hour 19 minutes ago

SPECTRIS PLC - Removal

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 34 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 19 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 34 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 35 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE